XmAb-2513
XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP) . XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research[1].
Product Specifications
UNSPSC
12352100
Target
TNF Receptor
Related Pathways
Apoptosis
Field of Research
Cancer
References & Citations
[1]Lawrence C E, et al. XmAb™ 2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies[J]. 2007.
Shipping Conditions
Room temperature
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P991638/
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Isoform
TNFRSF8/CD30
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
